Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

• Status: Recruiting
• Trial end date: 2021-03-15
• Target enrollment: 0
• Participant gender: All

Summary

Open-label, Phase 2, single treatment arm, 3 cohorts

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rain Therapeutics Inc.
• Treatments: Bromides

Criteria

Key Inclusion Criteria:

• Histologically and/or cytologically confirmed primary diagnosis of NSCLC, Stage IV, Stage IIIB or IIIC not amenable to definitive curative intent therapy, or recurrent disease after prior diagnosis of Stage I-III disease. Cohort C locally advanced or metastatic solid tumor.

• Progression of disease on or after a platinum-based chemotherapy regimen (Cohorts A and B) or after standard of care (Cohort C)

• EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or NRG1 or ERBB family gene fusions (Cohort C)

• Measurable disease according to RECIST v.1.1

• ECOG performance status of 0 or 1

• Serum creatinine ≤ 1.5 x ULN (or calculated creatinine clearance ≥ 60 mL/min using Cockcroft Gault equation)

• Total bilirubin: ≤ 1.5 x ULN or ≤ 3 x ULN in the presence of liver metastases

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN, in the presence of liver metastases

• Absolute neutrophil count (ANC) ≥ 1,500 cells/μL

• Hemoglobin ≥ 9 g/dL or 5.6 mmol/L

• Platelet count ≥ 100,000/μL

• No evidence of second or third degree atrioventricular block

• No clinically significant arrhythmia (i.e.; pauses of > 4 seconds, VT of any duration, SVT > 4 beats/minute)

• QRS interval ≤ 110 ms

• QTcF interval of < 450 ms

• PR interval ≤ 200 ms

• Adequate pretreatment tumor sample (125 µm of FFPE block or at least 8 prepared slides)

Key Exclusion Criteria:

• Another known activating oncogene driver mutation

• (Cohorts A and B Only) Previously received anti EGFR or anti HER2 tyrosine kinase inhibitors

• (Cohorts A and B Only) Previously received anti EGFR or anti HER2 monoclonal antibodies or EGFR or HER2 antibody drug conjugates

• Investigational therapy administered within the 28 days or 5 half lives

• Chemotherapy or radiation within 14 days prior to Cycle 1 Day 1

• Immunotherapy within 21 days

• Clinically active or symptomatic interstitial lung disease (ILD) or interstitial pneumonitis, or a history of clinically significant ILD or radiation pneumonitis

• Untreated and/or symptomatic CNS malignancies (primary or metastatic);

• Receiving medication that prolongs QT interval, with a risk of causing Torsade de Pointes (TdP)

• Personal or familial history of Long QT Syndrome

• NYHA class III or IV or LVEF < 55%

• Myocardial infarction, severe or unstable angina within 6 months

• History of TdP, ventricular arrhythmia

• Significant thrombotic or embolic events within 3 months

• Uncontrolled or severe cardiovascular disease

• Concurrent malignancy expected to require treatment within 2 years or interfere with study outcomes

• History of severe allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition as tarloxotinib

• Known HIV infection or active Hepatitis B or C